Genmab — November 2022
-
and from Mathai Mammen, when he was still at JNJ, -This study with the HexaBody is being run by Genmab in close collaboration with us. And it's a next generation even more effective CD38 blocker, deep activity on CD38 positive cells. And we'll see data towards the end of this year that'll help us understand whether there's a path forward, both in multiple myeloma, by the way, and diffuse large cell B cell lymphoma. And so, this is exciting for us.
-
ASH 1366 Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies https://ash.confex.com/ash/2022/webprogram/Paper159396.html
-
ASH 611 Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial https://ash.confex.com/ash/2022/webprogram/Paper158232.html the overall response rate was 90% (26/29), with 69% (20/29) having a complete metabolic response (CMR) as their best overall response.
-
ASH 609 Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update - https://ash.confex.com/ash/2022/webprogram/Paper158203.html - the overall response rate was 95% (39/41), with 73% of patients (30/41) achieving a complete metabolic response (CMR) as their best overall response -Slightly higher as before
-
ASH 443 Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results - https://ash.confex.com/ash/2022/webprogram/Paper158278.html
-
ASH 348 Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1) - https://ash.confex.com/ash/2022/webprogram/Paper158298.html
-
-
Jeg har lidt AFMD, der kom med flere nyheder i dag. https://finance.yahoo.com/news/affimed-announces-presentation-phase-1-130500953.html Måske kunne nogen have lidt interesse i den. På eget ansvar
-
Kort video: I den sidste uges tid er det væltet ind med q3-regnskaber, bl.a. fra Danske Bank og Novo Nordisk. Derudover kommer Helge Larsen ind på Eli Lilly, Zealand Pharma og Bavarian Nordic - sidstnævnte især omhandlende shorting.https://www.proinvestor.com/boards/107506
-CD3xCD30)?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind